Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins Eloxatin patent case

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin until August 2012 following a patent challenge from Sun Pharmaceuticals

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin (oxaliplatin) until August 2012 following a patent challenge from Sun Pharmaceuticals.

Sun Pharma was appealing a district court ruling from April 2010 requiring Sun to cease selling its generic oxaliplatin products as of June 30, 2010.

Sanofi had previously reached settlement agreements with several other pharmaceutical companies, including Teva Pharmaceutical and Sandoz, prohibiting the sale of generic Eloxatin products in the US until August, 2012.

In recently released financial results, Sanofi reported the drug had sales €436m for Sanofi during the first half of 2011.

The company said it still sees Eloxatin as an important therapeutic option for healthcare professionals treating patients with colorectal cancer.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics